Angiotensin receptor blockers on cognitive function in Alzheimer’s disease

Fabricio Ferreira De Oliveira, MD, PhD from the Federal University of São Paulo, São Paulo, Brazil discusses the pharmacogenetics of angiotensin receptor blockers in patients with Alzheimer’s disease. Dr Ferreira De Oliveira explains that angiotensin-converting enzyme is an amyloid-β-degrading enzyme and for this study, they looked at the effect of angiotensin receptor blockers on cognitive function.
Recorded at the 2017 Congress of the European Academy of Neurology (EAN) in Amsterdam, the Netherlands.

Share this video